A Phase 3 interventional study of Aflibercept (Eylea, BAY 86-5321) and Sham Injection in Glaucoma, Neovascular, sponsored by Bayer. Completed at 19 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-09-15.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.
39 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.
This study's enrollment of 54 is above the median of 40 across 32 interventional studies indexed under Glaucoma, Neovascular.
Browse Glaucoma, Neovascular studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Aflibercept 2 mg Intravitreal (IVT) injection group
Drug: Aflibercept (Eylea, BAY 86-5321)
Sham injection group
Drug: Sham Injection
After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1
It compared the change in IOP from baseline to pre-dose at Week 1 between the aflibercept group vs the sham group.
Time frame: From baseline to pre-dose at Week 1
Percentage of Subjects Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Pre-dose at Week 1
NVI were assessed in the study eye using the NVI grading systems (grade 0 to grade 4). A subject who shows the improvement by at least one grade is considered to be improved. Percentage of subjects who had improved NVI grade was reported.
Time frame: From baseline to pre-dose at Week 1
Study was conducted at nineteen study centers in Japan, between 02 April 2015 (first subject first visit) and 06 Sep 2016 (last subject last visit).
| Milestone | Aflibercept 2 mg Intravitreal (IVT) Injection Group | Sham Injection Group |
|---|---|---|
| Started | 27 | 27 |
| Treated | 27 | 27 |
| Received sham injection at week 1 | 10 | 0 |
| Received afl injection at week 1 | 0 | 22 |
| Received active injection at week 5 | 4 | 4 |
| Received active injection at week 9 | 2 | 1 |
| Completed | 20 | 22 |
| Not completed | 7 | 5 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Progressive disease | 6 | 3 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Treatment unblinded | 0 | 1 |
It compared the change in IOP from baseline to pre-dose at Week 1 between the aflibercept group vs the sham group.
| mmHg | Aflibercept 2 mg Intravitreal (IVT) Injection Group | Sham Injection Group |
|---|---|---|
| Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1 | -8.5 ± 8.7 | -4.9 ± 10.8 |
NVI were assessed in the study eye using the NVI grading systems (grade 0 to grade 4). A subject who shows the improvement by at least one grade is considered to be improved. Percentage of subjects who had improved NVI grade was reported.
| Percentage of participants | Aflibercept 2 mg Intravitreal (IVT) Injection Group | Sham Injection Group |
|---|---|---|
| Percentage of Subjects Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Pre-dose at Week 1 | 70.4 | 11.5 |
Collected over Adverse event data were collected after the first dose of study drug and no later than 30 days after the last dose of study drug. AEs from the first dose of study drug until pre-dose at Week 1 were also reported.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept 2 mg Intravitreal (IVT) Injection Group | — | 3/27 (11.1%) | 10/27 (37%) |
| Sham Injection Group | — | 3/27 (11.1%) | 12/27 (44.4%) |
| Aflibercept 2 mg IVT Injection Group (Till Pre-dose at Week 1) | — | 0/27 (0%) | 6/27 (22.2%) |
| Sham Injection Group (Till Pre-dose at Week 1) | — | 0/27 (0%) | 7/27 (25.9%) |
| Event | Aflibercept 2 mg Intravitreal (IVT) Injection Group | Sham Injection Group | Aflibercept 2 mg IVT Injection Group (Till Pre-dose at Week 1) | Sham Injection Group (Till Pre-dose at Week 1) |
|---|---|---|---|---|
| Myocardial ischaemiaCardiac disorders | 0/27 | 1/27 | 0/27 | 0/27 |
| Diabetic retinopathyEye disorders | 0/27 | 1/27 | 0/27 | 0/27 |
| Retinal artery occlusionEye disorders | 1/27 | 0/27 | 0/27 | 0/27 |
| Retinal vein occlusionEye disorders | 1/27 | 0/27 | 0/27 | 0/27 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/27 | 0/27 | 0/27 | 0/27 |
| Eating disorderPsychiatric disorders | 0/27 | 1/27 | 0/27 | 0/27 |
| Event | Aflibercept 2 mg Intravitreal (IVT) Injection Group | Sham Injection Group | Aflibercept 2 mg IVT Injection Group (Till Pre-dose at Week 1) | Sham Injection Group (Till Pre-dose at Week 1) |
|---|---|---|---|---|
| Eye painEye disorders | 0/27 | 4/27 | 0/27 | 1/27 |
| Punctate keratitisEye disorders | 2/27 | 3/27 | 2/27 | 1/27 |
| Procedural painInjury, poisoning and procedural complications | 3/27 | 0/27 | 0/27 | 0/27 |
| Conjunctival haemorrhageEye disorders | 2/27 | 1/27 | 2/27 | 0/27 |
| HyphaemaEye disorders | 0/27 | 2/27 | 0/27 | 2/27 |
| ConstipationGastrointestinal disorders | 1/27 | 2/27 | 0/27 | 0/27 |
| DiarrhoeaGastrointestinal disorders | 2/27 | 0/27 | 1/27 | 0/27 |
| Injection site painGeneral disorders | 2/27 | 1/27 | 2/27 | 1/27 |
| Intraocular pressure increasedInvestigations | 0/27 | 2/27 | 0/27 | 1/27 |
| HeadacheNervous system disorders | 1/27 | 2/27 | 0/27 | 2/27 |
| Age, Continuous(Years) | Aflibercept 2 mg Intravitreal (IVT) Injection Group | Sham Injection Group | Total |
|---|---|---|---|
| Mean | 68.1 ± 12.7 | 66.2 ± 13.7 | 67.1 ± 13.1 |
| Sex: Female, Male(Participants) | Aflibercept 2 mg Intravitreal (IVT) Injection Group | Sham Injection Group | Total |
|---|---|---|---|
| Female | 5 | 4 | 9 |
| Male | 22 | 23 | 45 |
Ran from Apr 2015 to primary completion in Jun 2016, 14 months.
Results were first posted in Jul 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept